Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Breast 2

Conditions

Breast Neoplasms 1Breast Cancer Female 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Alitretinoin × Breast × Clear all
NCT05016349 2021-08-23

Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.

Kafrelsheikh University

Phase 3 Unknown
160 enrolled
Breast

Breast Cancer Female

NCT00001504 2008-03-04

A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
18 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡